Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial

por Bühler, A, Wendtner, C-M, Kipps, T J, Rassenti, L, Fraser, G A M, Michallet, A-S, Hillmen, P, Dürig, J, Gregory, S A, Kalaycio, M, Aurran-Schleinitz, T, Trentin, L, Gribben, J G, Chanan-Khan, A, Purse, B, Zhang, J, De Bedout, S, Mei, J, Hallek, M, Stilgenbauer, S
Publicado 2016